SPYRE THERAPEUTICS, INC. (SYRE) Return on equity 2016–2025
SPYRE THERAPEUTICS, INC. (SYRE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-21.7%FY2025 · since FY2016: -34.5% → -21.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -21.7% | +18.5 pp |
| FY2024 | -40.2% | +143.9 pp |
| FY2023 | -184.1% | -17.5 pp |
| FY2022 | -166.6% | -88.2 pp |
| FY2021 | -78.4% | -20.5 pp |
| FY2020 | -57.9% | +72.4 pp |
| FY2019 | -130.2% | -64.5 pp |
| FY2018 | -65.8% | -11.7 pp |
| FY2017 | -54.1% | -19.6 pp |
| FY2016 | -34.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SYRE financial trends
SYRE RevenueSYRE Net incomeSYRE Net marginSYRE Gross profitSYRE Gross marginSYRE Operating incomeSYRE Operating marginSYRE Operating cash flowSYRE Free cash flowSYRE Capital expendituresSYRE Stock buybacksSYRE Dividends paidSYRE Total assetsSYRE Total liabilitiesSYRE Shareholders’ equitySYRE overview →